KR20110014199A - 비강 비염 치료용 재조합 인간 ｃｃ10 및 이의 조성물 - Google Patents

비강 비염 치료용 재조합 인간 ｃｃ10 및 이의 조성물 Download PDF

Info

Publication number
KR20110014199A
KR20110014199A KR1020107028003A KR20107028003A KR20110014199A KR 20110014199 A KR20110014199 A KR 20110014199A KR 1020107028003 A KR1020107028003 A KR 1020107028003A KR 20107028003 A KR20107028003 A KR 20107028003A KR 20110014199 A KR20110014199 A KR 20110014199A
Authority
KR
South Korea
Prior art keywords
rhcc10
nasal
administered
patient
micrograms
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020107028003A
Other languages
English (en)
Korean (ko)
Inventor
에이프릴 엘. 필론
Original Assignee
클라라산스, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 클라라산스, 인크. filed Critical 클라라산스, 인크.
Publication of KR20110014199A publication Critical patent/KR20110014199A/ko
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Otolaryngology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020107028003A 2008-05-13 2009-05-12 비강 비염 치료용 재조합 인간 ｃｃ10 및 이의 조성물 Ceased KR20110014199A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5286108P 2008-05-13 2008-05-13
US61/052,861 2008-05-13

Publications (1)

Publication Number Publication Date
KR20110014199A true KR20110014199A (ko) 2011-02-10

Family

ID=41319290

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020107028003A Ceased KR20110014199A (ko) 2008-05-13 2009-05-12 비강 비염 치료용 재조합 인간 ｃｃ10 및 이의 조성물

Country Status (12)

Country Link
US (3) US20110240012A1 (cg-RX-API-DMAC10.html)
EP (2) EP2303308A4 (cg-RX-API-DMAC10.html)
JP (1) JP5773437B2 (cg-RX-API-DMAC10.html)
KR (1) KR20110014199A (cg-RX-API-DMAC10.html)
CN (1) CN102292099A (cg-RX-API-DMAC10.html)
AU (1) AU2009246543B2 (cg-RX-API-DMAC10.html)
BR (1) BRPI0911945A2 (cg-RX-API-DMAC10.html)
CA (1) CA2724277A1 (cg-RX-API-DMAC10.html)
IL (1) IL208940A0 (cg-RX-API-DMAC10.html)
MX (1) MX2010012234A (cg-RX-API-DMAC10.html)
NZ (2) NZ588895A (cg-RX-API-DMAC10.html)
WO (1) WO2009140269A2 (cg-RX-API-DMAC10.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060281681A1 (en) 1997-05-28 2006-12-14 Pilon Aprile L Methods and compositions for the reduction of neutrophil influx and for the treatment of bronchpulmonary dysplasia, respiratory distress syndrome, chronic lung disease, pulmonary fibrosis, asthma and chronic obstructive pulmonary disease
EP2303308A4 (en) 2008-05-13 2012-11-07 Clarassance Inc HUMAN RECOMBINANT PROTEIN CC10 AND COMPOSITIONS CONTAINING IT FOR THE TREATMENT OF NASAL RHINITIS
US9168285B2 (en) 2009-10-15 2015-10-27 Therabron Therapeutics, Inc. Recombinant human CC10 protein for treatment of influenza and ebola
WO2011047065A1 (en) * 2009-10-15 2011-04-21 Clarassance, Inc. Recombinant human cc10 protein for treatment of influenza
WO2012170842A2 (en) 2011-06-09 2012-12-13 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Peptide for protection of allergic respiratory disorders
EP2938339B1 (en) 2012-12-27 2020-08-19 Massachusetts Eye & Ear Infirmary Treatment of rhinosinusitis with p-glycoprotein inhibitors
US20140274981A1 (en) * 2013-03-15 2014-09-18 Janssen Pharmaceutica Nv Pharmaceutical composition of s-ketamine hydrochloride
WO2016205430A1 (en) * 2015-06-15 2016-12-22 Therabron Therapeutics, Inc. Recombinant human cc10 protein facilitates repair and protects against damage to the respiratory epithelium due to exposure to both cigarette and other smoke
US11408900B2 (en) 2016-01-15 2022-08-09 Massachusetts Eye And Ear Infirmary Secreted P-glycoprotein is a non-invasive biomarker of chronic rhinosinusitis
JP7631212B2 (ja) * 2019-02-27 2025-02-18 オティカラ，インコーポレーテッド 鼻、副鼻腔、および鼻咽頭組織の感染および／または炎症を治療するための方法
EP3934632A4 (en) 2019-03-05 2022-11-23 Janssen Pharmaceuticals, Inc. Esketamine for the treatment of depression
US12295933B2 (en) 2019-03-25 2025-05-13 Massachusetts Eye And Ear Infirmary Methods and compositions to treat and diagnose diseases or pathologies associated with inflammation of the sinuses and nasal cavity

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4691009A (en) 1984-12-26 1987-09-01 Repligen Corporation Hybrid proteins produced by an ultrahigh prokaryotic expression system
EP0243449A1 (en) 1985-10-18 1987-11-04 The Upjohn Company Cyclic hydrocarbons with an aminoalkyl sidechain
US4820514A (en) 1985-12-30 1989-04-11 Texas A&M University System Low dosage of interferon to enhance vaccine efficiency
JP2656944B2 (ja) 1987-04-30 1997-09-24 クーパー ラボラトリーズ タンパク質性治療剤のエアロゾール化
US5266562A (en) 1987-11-19 1993-11-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Anti-inflammatory agents
US5354269A (en) 1991-12-20 1994-10-11 Fibrogenex, Inc. Method for treating cancer resections
US5491130A (en) 1992-11-10 1996-02-13 The United States Of America As Represented By The Department Of Health And Human Services Peptide inhibitors of fibronectin and related collagen-binding proteins
US5482930A (en) 1993-06-09 1996-01-09 The Regents Of The University Of California Anti-inflammatory composition and method with des-Tyr dynorphin and analogues
US5470885A (en) 1993-09-29 1995-11-28 The Research Foundation Of The State University Of New York Fluorocarbons as anti-inflammatory agents
FR2724665B1 (fr) 1994-09-16 1996-12-20 Rhone Poulenc Rorer Sa Procede de production de proteines recombinantes, plasmides et cellules modifiees
US5935860A (en) 1995-03-07 1999-08-10 The George Washington University Use of uteroglobin expression as a molecular marker for prostatic intraepithelial neoplasia
US5696092A (en) 1995-03-07 1997-12-09 George Washington University Methods and compositions for inhibiting metastasis of epithelial cell-derived cancers
WO1997001627A1 (en) 1995-06-27 1997-01-16 Igen International, Inc. High-level expression and efficient recovery of ubiquitin fusion proteins from escherichia coli
US5817750A (en) 1995-08-28 1998-10-06 La Jolla Cancer Research Foundation Structural mimics of RGD-binding sites
WO1997034997A1 (en) 1996-03-21 1997-09-25 Human Genome Sciences, Inc. Human endometrial specific steroid-binding factor i, ii and iii
WO1998021350A1 (en) 1996-11-13 1998-05-22 Board Of Regents, The University Of Texas System Diminishing viral gene expression by promoter replacement
US20020160948A1 (en) * 1998-07-21 2002-10-31 Aprile Pilon Recombinant human uteroglobin in treatment of inflammatory and fibrotic conditions
US20040047857A1 (en) 1997-05-28 2004-03-11 Pilon Aprile L. Methods and compositions for the treatment of fibrotic conditions & impaired lung function & to enhance lymphocyte production
US20060025348A1 (en) * 1997-05-28 2006-02-02 Pilon Aprile L Methods and compositions for the treatment of fibrotic conditions & impaired lung function & to enhance lymphocyte production
US7122344B2 (en) 1997-05-28 2006-10-17 Claragen, Inc. Methods for the production of purified recombinant human uteroglobin for the treatment of inflammatory and fibrotic conditions
US6255281B1 (en) 1997-05-28 2001-07-03 Claragen, Inc. And U.S. Government Use of recombinant human uteroglobin in treatment of inflammatory and fibrotic conditions
US20060281681A1 (en) * 1997-05-28 2006-12-14 Pilon Aprile L Methods and compositions for the reduction of neutrophil influx and for the treatment of bronchpulmonary dysplasia, respiratory distress syndrome, chronic lung disease, pulmonary fibrosis, asthma and chronic obstructive pulmonary disease
US20030207795A1 (en) 1997-05-28 2003-11-06 Pilon Aprile L. Methods for the production of purified recombinant human uteroglobin for the treatment of inflammatory and fibrotic conditions
US20050261180A1 (en) 1997-05-28 2005-11-24 Pilon Aprile L Use of recombinant human uteroglobin in treatment of inflammatory and fibrotic conditions
US20030008816A1 (en) 1997-05-28 2003-01-09 Pilon Aprile L. Methods and compositions for the treatment of fibrotic conditions & impaired lung function & to enhance lymphocyte production
US20020169108A1 (en) 1997-05-28 2002-11-14 Pilon Aprile L. Methods and compositions for the treatment of fibrotic conditions & impaired lung function & to enhance lymphocyte production
HUP0101419A3 (en) 1998-04-16 2002-08-28 Texas Biotechnology Corp Houst Compounds that inhibit the binding of integrins to their receptors and pharmaceutical compositions containing them
AU5836700A (en) 1999-06-01 2000-12-18 Patrick T. Prendergast Peptides for therapeutic use
WO2001032677A1 (en) 1999-11-04 2001-05-10 Human Genome Sciences, Inc. Uteroglobin-like polynucleotides, polypeptides, and antibodies
CA2405946A1 (en) 2000-04-14 2001-10-25 Clarassance, Inc. Methods and compositions for the treatment of fibrotic conditions and impaired lung function and to enhance lymphocyte production
AU2001282977A1 (en) 2000-07-26 2002-02-05 The Burnham Institute Screening methods based on superactivated alphavbeta3 integrin
AU2003202201A1 (en) * 2002-01-02 2003-07-24 The Johns Hopkins University Cc10 inhibits th2 cytokines and eotaxins involved in allergic diseases
US20090227025A1 (en) 2003-06-06 2009-09-10 The Board Of Regents Of The University Of Texas System Ex vivo human lung/immune system model using tissue engineering for studying microbial pathogens with lung tropism
AU2005272598B2 (en) * 2004-08-12 2011-11-17 Helsinn Therapeutics (U.S.), Inc. Method of stimulating the motility of the gastrointestinal system using growth hormone secretagogues
US7887859B2 (en) * 2006-11-02 2011-02-15 Riolan Technologies, Inc. Methods of treating epiphora
EP1935242A1 (en) * 2006-12-21 2008-06-25 Philip Morris Products S.A. Transgenic animal model
JP2011517410A (ja) 2008-04-08 2011-06-09 アミリス バイオテクノロジーズ， インコーポレイテッド 異種配列の発現
EP2303308A4 (en) 2008-05-13 2012-11-07 Clarassance Inc HUMAN RECOMBINANT PROTEIN CC10 AND COMPOSITIONS CONTAINING IT FOR THE TREATMENT OF NASAL RHINITIS
WO2011047065A1 (en) 2009-10-15 2011-04-21 Clarassance, Inc. Recombinant human cc10 protein for treatment of influenza

Also Published As

Publication number Publication date
JP5773437B2 (ja) 2015-09-02
US9844580B2 (en) 2017-12-19
AU2009246543B2 (en) 2015-08-06
WO2009140269A2 (en) 2009-11-19
EP2303308A4 (en) 2012-11-07
CN102292099A (zh) 2011-12-21
WO2009140269A3 (en) 2011-10-27
US20110240012A1 (en) 2011-10-06
EP3085382A1 (en) 2016-10-26
AU2009246543A1 (en) 2009-11-19
NZ600803A (en) 2013-12-20
JP2011520894A (ja) 2011-07-21
US20180125931A1 (en) 2018-05-10
MX2010012234A (es) 2011-03-03
NZ588895A (en) 2012-07-27
CA2724277A1 (en) 2009-11-19
BRPI0911945A2 (pt) 2015-10-13
EP2303308A2 (en) 2011-04-06
IL208940A0 (en) 2011-01-31
US20160158315A1 (en) 2016-06-09

Similar Documents

Publication Publication Date Title
JP5773437B2 (ja) 鼻性鼻炎の治療に使用するための組換えヒトｃｃ１０およびその組成物
AU2002361918B2 (en) Aerosolized decongestants for the treatment of sinusitis
US8450339B2 (en) Compositions for treatment of common cold
AU2002361918A1 (en) Aerosolized decongestants for the treatment of sinusitis
EP1207912A1 (en) Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitis
US9023815B2 (en) Method for treating rhinitis and sinusitis by rhamnolipids
TW201016209A (en) Intranasal compositions, dosage forms and methods of treatments
WO2011047065A1 (en) Recombinant human cc10 protein for treatment of influenza
KR20120107970A (ko) 상승적 항바이러스 조성물 및 이의 용도
JP2017527608A (ja) 経鼻組成物と該経鼻組成物の使用方法の改善
MXPA06008240A (es) Metodos de tratamiento.
CA3124202A1 (en) Compositions, devices, and methods for the treatment of overdose and reward-based disorders
JP2002161032A (ja) 粘膜適用組成物
JP2023545904A (ja) 局所適用して炎症性疾患及びサイトカイン放出症候群を治療する浸透圧性被膜における二重作用性ポリマー
AU2015204387A1 (en) Recombinant human cc10 and compositions thereof for use in the treatment of nasal rhinitis
Strauss Complications from Flu is a Taboo
Strauss Complications from Flu–an unnecessary evil!
Whittaker Chronic sinusitis: OTC management
HK1067984B (en) Compositions comprising ipatropium and xylometazoline for treatment of the common cold

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20101213

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20140212

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20150821

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20160727

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20150821

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

J201 Request for trial against refusal decision
PJ0201 Trial against decision of rejection

Patent event date: 20161026

Comment text: Request for Trial against Decision on Refusal

Patent event code: PJ02012R01D

Patent event date: 20160727

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Appeal kind category: Appeal against decision to decline refusal

Decision date: 20170201

Appeal identifier: 2016101006121

Request date: 20161026

J801 Dismissal of trial

Free format text: TRIAL NUMBER: 2016101006121; REJECTION OF TRIAL FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20161026

Effective date: 20170201

PJ0801 Rejection of trial

Decision date: 20170201

Appeal kind category: Appeal against decision to decline refusal

Appeal identifier: 2016101006121

Request date: 20161026